SecBot SecBot

TCRX drug pipeline

TScan Therapeutics, Inc. · 3 rated drugs
$0.1450
−9.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 3 (paused)
Time to marketUncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.

TSC-101 Updated Nov 13

What to watch

TSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.

Bull case
  • Phase 1 data were strong: 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, and all 5 patients assessed after a second infusion also achieved complete chimerism.
  • The FDA agreed on the pivotal study design for TSC-101, reducing regulatory risk if a partner picks up the program.
  • The company has $73M in cash extending into Q4 2027, providing time to find a partner for the heme program.
Bear case
  • The Phase 3 ALLOHA-2 trial is paused due to insufficient capital, with no guarantee a partner will be found to fund completion.
  • TScan cut 75% of its workforce and the CEO stated the company is 'pausing further development in the heme program', effectively deprioritizing TSC-101.
  • Three analysts downgraded the stock in early September 2026 (Needham to Hold, Wedbush to Neutral, HC Wainwright to Neutral).
● neutral
Impact
PhasePreclinical / IND-enabling
Time to marketPreclinical/IND-enabling stage; likely years away from any potential approval if development proceeds.

TSC-303-A02 Updated Nov 14

What to watch

TSC-303-A02 is an early-stage, preclinical candidate in TScan's new in vivo solid tumor pipeline. The next meaningful event would be an IND filing, which has not been publicly dated. The company's near-term binary is the November 20, 2026 shareholder vote on a reverse stock split to regain Nasdaq compliance. Watch for partnership announcements that could fund further development of the in vivo platform.

Bull case
  • TScan's strategic pivot to in vivo TCR-T technology targets a potentially disruptive approach that could eliminate complex ex vivo manufacturing, a major hurdle in cell therapy.
  • The company has cash runway into Q4 2027 (per the September 2026 restructuring) to advance IND-enabling studies for the in vivo solid tumor pipeline.
  • Analyst consensus still shows 7 Buy/Strong Buy ratings vs 4 Hold (as of November 2026), and the mean price target of $1.00 implies ~495% upside from the current $0.168 price.
Bear case
  • TSC-303-A02 is preclinical with no clinical data, no IND filing date, and no regulatory catalyst visible; the drug is years from any value-inflection event.
  • TScan is in acute financial distress: stock trades at ~$0.16, market cap ~$11.5M, facing a Nasdaq delisting notice with a reverse split vote scheduled for November 20, 2026.
  • The company cut 75% of its workforce, terminated its CFO and CMO, paused its only Phase 3 program (TSC-101), and lost its Amgen collaboration -- all in the past few months.